A 52-year-old man with moderate persistent asthma presents to the outpatient clinic. He is currently on inhaled beclomethasone twice daily and uses salbutamol as needed, but reports persistent daytime symptoms 3–4 times per week and nocturnal awakening twice per week. Spirometry shows FEV₁ 68% predicted. His physician decides to add a long-acting bronchodilator. Which agent would be most appropriate as add-on therapy, and why?

Explanation

## Rationale for LABA as Add-On Therapy **Key Point:** In asthma inadequately controlled on inhaled corticosteroids (ICS) alone, a long-acting beta-2 agonist (LABA) is the first-line add-on bronchodilator, as per GINA and NAEPP guidelines. ### Mechanism of LABA in Asthma Control LABAs (salmeterol, formoterol) provide: - Sustained bronchodilation for 12 hours via β₂-adrenergic receptor stimulation - Prevention of nocturnal symptoms and early-morning airway obstruction - Synergistic anti-inflammatory effect when combined with ICS - Improved FEV₁ and reduced exacerbation frequency **High-Yield:** The combination of ICS + LABA is the evidence-based Step 3 therapy for asthma and is superior to increasing ICS dose alone. ### Why This Patient Qualifies for LABA | Feature | Patient Status | Significance | |---------|---|---| | Daytime symptoms | 3–4 times/week | Indicates inadequate control | | Nocturnal awakening | 2×/week | Suggests need for sustained bronchodilation | | FEV₁ | 68% predicted | Objective evidence of airflow limitation | | Current therapy | ICS monotherapy | LABA is next logical step | **Clinical Pearl:** LABAs should NEVER be used as monotherapy in asthma due to increased risk of asthma-related deaths; they must always be paired with an ICS. ### Comparison with Other Options | Agent | Role in Asthma | Why Not Here | |-------|---|---| | LABA (salmeterol) | First-line add-on to ICS | ✓ Correct choice | | LAMA (tiotropium) | Second-line add-on if LABA inadequate | Not yet indicated; LABA is preferred first | | Theophylline | Third-line; narrow therapeutic window | Outdated; poor safety profile; not first-line | | SABA (terbutaline) | Rescue/as-needed only | Does not provide sustained control | **Mnemonic:** **ICS-LABA = Step 3** — When ICS monotherapy fails, add LABA (not LAMA, not theophylline). ## Summary The patient has inadequate asthma control on ICS alone with objective evidence of airflow limitation and nocturnal symptoms. LABA is the evidence-based, guideline-recommended add-on that provides sustained bronchodilation and synergizes with ICS to improve outcomes. [cite:GINA 2023 Asthma Management Guidelines]